BIONDVAX PHARMACEUTICALS LTD's ticker is BVXV and the CUSIP is 09073Q105. A total of 18 filers reported holding BIONDVAX PHARMACEUTICALS LTD in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,000 | -33.3% | 2,540 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 2,540 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -33.3% | 2,540 | 0.0% | 0.00% | – |
| Q4 2021 | $6,000 | 0.0% | 2,540 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | -14.3% | 2,540 | 0.0% | 0.00% | – |
| Q2 2021 | $7,000 | -30.0% | 2,540 | 0.0% | 0.00% | – |
| Q1 2021 | $10,000 | +42.9% | 2,540 | 0.0% | 0.00% | – |
| Q4 2020 | $7,000 | -95.0% | 2,540 | -29.6% | 0.00% | – |
| Q3 2020 | $141,000 | +80.8% | 3,607 | +4.9% | 0.00% | – |
| Q2 2020 | $78,000 | +188.9% | 3,440 | -1.0% | 0.00% | – |
| Q1 2020 | $27,000 | +237.5% | 3,475 | +286.1% | 0.00% | – |
| Q4 2019 | $8,000 | +60.0% | 900 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | 0.0% | 900 | 0.0% | 0.00% | – |
| Q2 2019 | $5,000 | 0.0% | 900 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +25.0% | 900 | 0.0% | 0.00% | – |
| Q4 2018 | $4,000 | -20.0% | 900 | 0.0% | 0.00% | – |
| Q3 2018 | $5,000 | -16.7% | 900 | 0.0% | 0.00% | – |
| Q2 2018 | $6,000 | +20.0% | 900 | 0.0% | 0.00% | – |
| Q1 2018 | $5,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ibex Investors LLC | 322,413 | $12,603,000 | 6.64% |
| MORGAN JESS S & CO INC | 74,464 | $2,911,000 | 2.90% |
| Mutual Advisors, LLC | 7,151 | $280,000 | 0.02% |
| BANK HAPOALIM BM | 6,510 | $254,000 | 0.01% |
| NEXT Financial Group, Inc | 1,350 | $53,000 | 0.01% |
| ARK Investment Management | 19,856 | $776,000 | 0.01% |
| HighTower Advisors, LLC | 17,900 | $701,000 | 0.00% |
| Edge Wealth Management LLC | 250 | $10,000 | 0.00% |
| CAPTRUST FINANCIAL ADVISORS | 1,190 | $47,000 | 0.00% |
| ROYAL BANK OF CANADA | 3,607 | $141,000 | 0.00% |